Objective-The N-terminal lectin-like domain (domain 1 [D1]) of thrombomodulin (TM) is known to have an antiinflammatory function. We previously showed that recombinant TM domain 1 (rTMD1) interacts with a carbohydrate molecule, Lewis Y (Le y ), which is found to be expressed on adhesion molecules and involved in cell adhesion. Here, we tested the effect of rTMD1/Le y interaction on leukocyte recruitment in inflammation. Approach and Results-The expression of Le y on the surface of human umbilical vein endothelial cells was increased by tumor necrosis factor-α stimulation. Direct binding of rTMD1 to Le y on the cell surface was observed. rTMD1 inhibited Le y -mediated leukocyte adhesion on the Le y -immobilized flow chamber and activated endothelium under a shear flow.
V ascular inflammation induced by proinflammatory mediators is an initial pathological condition that leads to chronic vascular diseases, such as atherosclerosis and restenosis. 1 In the inflammatory conditions, vascular endothelium becomes activated and is characterized by increased expression of adhesion molecules, chemokines, and cytokines. Circulating leukocytes are subsequently attracted and stimulated by activated endothelium, triggering leukocyte recruitment into the vessel wall. The recruitment requires sequential steps, including rolling, firm adhesion, and transendothelial migration, that involve the interaction of various adhesion and cell-cell junction molecules on the surface of leukocytes and endothelial cells. 2 Leukocyte infiltration and accumulation in injured vessel wall lead to various proinflammatory stimuli release and consequently augment the inflammatory responses. The sustained recruitment of these inflammatory cells may contribute to vascular diseases progression. 3, 4 Thus, reducing leukocyte recruitment by interfering with the interaction between leukocytes and endothelial cells is considered to be an effective strategy to suppress inflammation and disease progression.
Thrombomodulin (TM) is a type I transmembrane glycoprotein consisting of multiple domains. TM/thrombin complex on the endothelial cell surface is essential for anticoagulation, and activated protein C generated by this complex functions as a key factor in anticoagulation, anti-inflammation, and antiapoptosis. 5 In addition, several biological functions of TM in other cell types have been identified. The N-terminal C-type lectin-like domain (domain 1 [D1]) of TM has been known to have anti-inflammatory properties. 6 Conway et al 7 initially reported that TM domain 1 (TMD1) can inhibit inflammation using transgenic mice lacking TMD1 (TM Led/Led ). These transgenic mice have more severe inflammatory responses, including reduced survival after lipopolysaccharide challenge, increased leukocyte accumulation in lung injury, and larger infarcts after myocardial ischemia/reperfusion. Moreover,
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Wei-Ling Lin, Chuan-Fa Chang, Chung-Sheng Shi, Guey-Yueh Shi, Hua-Lin Wu recombinant TMD1 (rTMD1) has been shown to attenuate inflammation by inhibiting complement activation 8 and sequestering high mobility group box B1 protein. 9 However, except for high mobility group box B1, other interacting molecules of TMD1 that may participate in anti-inflammation are still unknown. Previously, we demonstrated that Lewis Y (Le y ; Fucα1-2Galβ1-4(Fucα1-3)GlcNAcβ1-R) is a specific carbohydrate ligand of rTMD1. 10, 11 Le y is known to be highly expressed in epithelial cells, especially in cancer tissues, 12 where Le y mediates cell adhesion, 13, 14 proliferation, 15, 16 and apoptosis. 13, 17, 18 Meanwhile, recent studies have demonstrated that Le y is upregulated in synovial endothelium and joint fluid in rheumatoid arthritis. 19, 20 Le y is also found to be expressed on intercellular adhesion molecule-2 (ICAM-2) on endothelial cells. ICAM-2 is a ligand of dendritic cell-specific C-type lectin, dendritic cell-specific ICAM-3-grabbing nonintegrin. The interaction of dendritic cell-specific ICAM-3-grabbing nonintegrin with ICAM-2 on vascular endothelium is Le y dependent and is essential for dendritic cell-specific ICAM-3-grabbing nonintegrin recruitment into tissues to mediate immune responses. 21, 22 These findings suggest that interaction of Le y with lectin-containing receptor might be involved in recruitment of leukocytes in inflammatory responses. Because Le y is a specific ligand of rTMD1, we hypothesize that rTMD1/ Le y interaction on endothelial cells would influence leukocyte recruitment, thereby suppressing inflammation.
To test our hypothesis, we examined the expression and function of Le y in endothelial cells under inflammatory conditions and studied the effect of rTMD1/Le y binding on anti-inflammation in vitro and in vivo. We discovered that leukocyte recruitment was interfered by rTMD1/Le y interaction. Animal inflammation models of thioglycollate-induced peritonitis, carotid ligation injury, and atherosclerosis were applied to further evidence the protective effect of rTMD1. On the basis of these findings, we provide a novel mechanism that rTMD1 decreases leukocyte recruitment by binding to Le y and may further attenuate inflammatory responses.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Le y Mediates Leukocyte Adhesion on Inflammation
To investigate the role of Le y in inflammation, we initially tested whether Le y expression in endothelial cells would be induced by stimulation of the proinflammatory cytokine, tumor necrosis factor-α (TNF-α). As shown in Figure 1A , mRNA levels of fucosyltransferase 1 (FUT)1, FUT2, and FUT4 for Le y synthesis 23 in endothelial cells were measured. The expression of FUT4 and FUT1 was significantly increased after TNF-α stimulation for 12 and 24 hours, respectively; meanwhile, no significant difference was found in the expression of FUT2. In addition, higher Le y expression on the surface of endothelial cells was observed using flow cytometry and confocal microscope analysis ( Figure 1B and 1C) . These results indicate that Le y expression in endothelial cells is increased in response to TNF-α stimulation.
The induction of vascular adhesion molecules by inflammatory cytokines has been known to promote leukocyte adhesion to endothelium, which is critical for leukocyte trafficking to the inflamed vessels. 3 To further test whether the upregulation of Le y on inflammation would participate in leukocyte adhesion, we studied the adhesion of human neutrophils and peripheral blood mononuclear cells (PBMCs) to ( Figure 1D ). However, the amount of adherent PBMCs was less than neutrophils (13±1 versus 27±1 adherent cells/field). By preincubation of rTMD1 with immobilized Le y , the number of adherent leukocytes to Le y was decreased, suggesting that rTMD1 specifically inhibits Le y -mediated adhesion. Further, the interaction of THP-1 monocytes and human umbilical vein endothelial cells (HUVECs) was real-time monitored under flow (0.5 dynes/cm 2 ) to determine whether Le y would participate in leukocytes/endothelium adhesion. The result showed that more human leukemia monocytic THP-1 cells adhesion to TNF-α activated HUVECs than that under resting condition ( Figure 1E ). Moreover, the adhesion was reduced by Le y antibodies, indicating that endothelial Le y mediates leukocyte adhesion on endothelium. Thus, upregulation of Le y in inflammation may promote leukocyte adhesion.
rTMD1 Binding to Endothelial Le y Interferes With Leukocyte Adhesion and Transmigration
Our previous studies have shown that rTMD1 binds to soluble Le y specifically. 10, 11 To test whether rTMD1 could bind Le y on endothelial cells, we first analyzed the binding of fluorescein isothiocyanate-labeled rTMD1 on the cell surface using flow cytometry. The results showed that rTMD1 dose dependently bound on endothelial cells (Figure 2A and 2E). The binding was enhanced while cells were activated by TNF-α ( Figure 2B and 2F) and reduced in the presence of soluble Le y specifically ( Figure 2C and 2G), showing that soluble Le y can sequester rTMD1 from binding to endothelial cells. Next, we tested whether Le y would be the ligand of rTMD1 on endothelial cells. Le y antibody specifically recognized Le y on the cell surface; however, preincubation of unlabeled rTMD1 with cells decreased the capacity of the antibody recognizing Le y on cells ( Figure 2D and 2H), indicating that rTMD1 bound to cell surface Le y . Because rTMD1 inhibited leukocyte adhesion to immobilized Le y ( Figure 1D and 1E), we proceeded to examine whether rTMD1/endothelial Le y interaction may have an inhibitory effect on leukocyte/endothelium adhesion. As shown in Figure 3A , rTMD1 effectively reduced monocyte adhesion to TNF-α-activated HUVECs when compared with control at a shear rate of 0.5 dynes/cm 2 . Preincubation of soluble Le y with rTMD1 specifically reversed the inhibitory effect of rTMD1 on monocyte adhesion. Leukocyte adhesion followed by transendothelial migration occurs in leukocyte trafficking in inflammation. Therefore, we next used transwell assay to test whether transendothelial migration of monocyte would also be inhibited by rTMD1. The results showed that the number of transmigrated cells across endothelium to the lower chamber of transwell was significantly decreased by rTMD1. Similarly, the inhibitory effect of rTMD1 was reversed merely by soluble Le y preincubation ( Figure 3B ). Then, we assessed the effect of rTMD1 on inflammatory cell recruitment using acute thioglycollate-induced peritonitis model. 24 Twenty-four hours after thioglycollate stimulation, elicited inflammatory cells were detected in the peritoneal cavity. Preadministration of rTMD1 30 minutes before thioglycollate significantly reduced total white blood cell, neutrophils, and macrophage infiltration in peritoneal cavity ( Figure 3C ).
The binding affinity of mammalian-rTMD1 (m-rTMD1) to Le y was similar to Pichia-expressed rTMD1 ( Figure I in the online-only Data Supplement); therefore, m-rTMD1 was also used to examine whether the protein would interfere with leukocyte recruitment. The results showed that m-rTMD1 had similar inhibitory effects as Pichia-rTMD1 ( Figure II 
rTMD1 Inhibits Leukocyte Adhesion Induced by Carotid Ligation
Arterial ligation triggers leukocyte recruitment to the injured vessel that contributes to inflammation and neointima formation. 25 The upregulation of vascular adhesion molecules and leukocyte adhesion can be observed near the ligation site at the early time points after ligation. 26 Consistently, CD45-positive leukocytes were recruited to the ligated vessel at day 3 after ligation ( Figure 4A ). We examined whether rTMD1 would inhibit leukocyte adhesion by carotid artery ligation in mice. rTMD1 was administered intraperitoneally to mice once a day after ligation. At day 3, increased adherent polymorphonuclear leukocytes, identified as neutrophils, 27 were observed at the luminal surface in ligated vessels of saline-treated mice, whereas there was fewer leukocyte adhesion in unligated vessels ( Figure 4B ). Furthermore, the number of leukocyte recruited to the ligation site was dose dependently reduced by rTMD1 treatment (Figure 4B and 4C) . The data indicate that rTMD1 can reduce leukocyte adhesion on vascular endothelium after ligation-induced injury.
rTMD1 Reduces Macrophage Accumulation to Suppress Atherosclerosis
In chronic vascular inflammation, such as atherosclerosis, recruitment of leukocytes (especially monocytes/macrophages) promotes atherosclerotic plaque formation and consequently vessel occlusion. 1, 28 Therefore, the inhibitory effect of rTMD1 on leukocyte adhesion and transmigration in atherosclerosis progression was tested. Atherosclerosis was induced in apolipoprotein E-deficient mice feeding with a high-fat chow diet for 20 weeks. During this period, mice received rTMD1 by intraperitoneal injection every other day. At the end of the treatment, the atherosclerotic plaque formation in the descending aorta and the atherosclerotic lesion composition in aortic root were measured. The descending aortas derived from rTMD1-treated mice exhibited less plaque formation than that of saline-treated mice ( Figure 5A ). In addition, histology analysis of lesion components in the aortic root showed less lipid-rich lesion (Figure 5B and 5C) and fewer macrophage accumulation ( Figure 5D and 5E) in mice that received rTMD1 compared with saline control. In contrast, no significant difference in smooth muscle cell content between groups was observed ( Figure 5F and 5G) . Thus, rTMD1 can reduce macrophage accumulation in atherosclerotic lesions to attenuate atherosclerotic plaque formation. 
Le y Expression Is Increased in Inflamed Vessels
We analyzed Le y expression in the vessels after carotid ligation-induced and atherogenesis-induced inflammation. The unligated-contralateral and left ligated carotid arteries were harvested after 3 days of ligation, and then tissue extracts of the vessels were subjected to tissue Western blotting analysis for Le y . Several bands were highly expressed in ligated arteries in comparison with the unligated control ( Figure 6A, left) . ICAM-1, as an inflammatory marker of endothelium, was only expressed in ligated vessels ( Figure 6A, right upper) .
Immunofluorescence staining for Le y in the carotid arteries showed that Le y expression was obvious in the ligated vessel surface, whereas it was barely detectable in unligated vessel ( Figure 6B, left) . We used CD31 as the endothelial marker. The lining of CD31-positive endothelial cells was observed at the surface of both unligated and ligated vessels ( Figure 6B , right), suggesting that Le y expression was increased in inflammatory endothelial cells. Le y expression was further examined in the aortic arch sections from apolipoprotein E-deficient mice fed with high-fat chow diet. Oil red O staining for lipids showed the atherosclerotic plaque in the blood vessel ( Figure 6C, left) . Both of normal and atherosclerotic vessels were used for immunofluorescence staining. Le y expression had a sparse and weak pattern at the surface of normal vascular wall ( Figure 6C , middle upper, arrowheads). In atherosclerotic vessel, a stronger signal of Le y was detected at the plaque surface ( Figure 6C , middle lower, arrows), whereas Le y expression pattern at the surface without plaque was as similar as normal vessel ( Figure 6C , middle lower, arrowheads). Using CD31 as the endothelial cell marker ( Figure 6C, right) , we measured Le y expression area specifically at the endothelial layer and found higher Le y expression at the surface of plaque in atherosclerotic vessel when compared with its expression in normal vessel ( Figure 6D ).
Administrated rTMD1 Is Observed in Inflamed Vessels
To verify the treatment of rTMD1, we directly detected the presence of administered rTMD1 on the inflamed vessel surface. In the carotid ligation model, we found that rTMD1 was present on the ligated vessel surface, whereas it was undetectable on the unligated vessel surface ( Figure IIIA in the online-only Data Supplement, left). In addition, the expression pattern of rTMD1-positive signals in ligated vessels was similar to that of CD31 ( Figure ; hence, rTMD1 may have been lost or was difficult to be detected around the area. Taken together, these findings suggest that Le y expression is increased in inflamed vessels where it can facilitate leukocyte recruitment by promoting leukocyte/endothelium interaction, and rTMD1 treatment inhibits this effect by directly blocking Le y .
Discussion
In this study, we investigated the effect of rTMD1 and Le y interaction on leukocyte recruitment under inflammatory conditions. Le y expression was elevated on endothelium on inflammatory stimulation in vitro and in vivo, suggesting the involvement of Le y in inflammation. Following studies demonstrated that rTMD1/endothelial surface Le y interaction interfered with Le y -mediated leukocyte adhesion to reduce leukocyte recruitment and further ameliorated vascular inflammation. These studies provide a novel mechanism demonstrating and emphasizing the significant role of the carbohydrate-binding ability of the lectin-like domain of TM in anti-inflammation. About the role of carbohydrate and carbohydrate-binding protein interaction in leukocyte recruitment, selectins and selectin ligands are well-studied adhesion molecules that critically facilitate the initial steps of capture and rolling in leukocyte trafficking. 29 Selectins bind to the carbohydrate structure, sialyl-Lewis X (sialyl-Le x ), on selectin ligands with low affinity. This interaction plays an important role in slowing down leukocytes rolling velocity that helps the following attachment of leukocytes to endothelium. The expression of sialyl-Le x is mostly on leukocytes; however, it can also be found on high endothelial venues in lymph node to mediate lymphocytes homing. In inflammatory conditions, the selectin ligands and glycosyltransferases for sialyl-Le x synthesis are induced to participate in immune responses. 29, 30 In the pathological circumstance, selectin inhibitors are thought to be able to ameliorate inflammation. Direct interference of selectin and sialyl-Le x interaction is mostly the target to develop selectin inhibitors. Thus, small molecules of carbohydrate or protein are generated to be applied for further trials. 31 In comparison with our present studies, Le y is also a carbohydrate determinant that mediates leukocyte adhesion and was upregulated during inflammation. Different from sialy-Le x , Le y is preferentially presented on endothelium. We here speculate that the finding of Le y involving in the attachment of leukocyte to endothelium may be another carbohydrate molecule contributing in leukocyte recruitment beyond selectin and sialyl-Le x . The function of Le y probably has the synergistic effect on leukocyte/endothelium interaction. Notably, the binding affinity between m-rTMD1 and soluble Le y as reported by our previous studies showing the dissociation constant was 3.97×10 -6 mol/L, 11 which is higher than that in binding between sialyl-Le x and selectins. 29 Moreover, the binding affinity of rTMD1 and Le y was much higher than that of other carbohydrates, including other Lewis antigen members. 10 It might be proposed that leukocyte TM and endothelial Le y interaction could play a prominent role in mediating leukocyte/endothelium adhesion in inflammation. rTMD1 might be served as the soluble inhibitor that could functionally block membrane TM/Le y interaction and reduce inflammation. Further studies should be required to investigate this hypothesis.
The adhesive ability between neutrophils and PBMCs to Le y -coated surface was different as observed in our experiments ( Figure 1D ). Neutrophils had the higher and more rapid adhesion to Le y than PBMCs. According to the previous reports, different rolling characteristics of polymorphonuclear leukocytes and mononuclear leukocytes may be related to their distinct binding interaction to endothelial selectins. 32 Thus, the difference in the number between neutrophils and PBMC adhesion on Le y -coated slide probably suggests that there may be different types or distribution of receptors that have dissimilar binding properties for Le y among the leukocyte subpopulations.
The mRNA levels of FUT1, FUT2, and FUT4 were used to determine Le y expression in HUVECs before and after TNF-α activation ( Figure 1A) . Within the structure of Le y (Fucα1,2Galβ1,4(Fucα1,3)GlcNAcβ1-R), FUT1 and FUT2 are responsible for Fucα(1,2)-linkage, and FUT4 is responsible for Fucα(1,3)-linkage. 23, 33 FUT4 and FUT1 were found to be significantly elevated after 12 and 24 hours of stimulation, but FUT2 mRNA level was not affected by TNF-α. Because the expression of FUT genes is tissue-and cell-type dependent 23 and FUT2 expression is much lower than FUT1 in HUVECs, 22 it is expectable that there was no significant change of FUT2 mRNA levels in TNF-α-activated HUVECs.
Previous studies have shown that FUT4 and FUT7 controlled susceptibility in atherosclerosis in apolipoprotein E-deficient mice, indicating that the elevation of these 2 FUTs contributes to atherosclerosis. 34 FUT4 is one of the glycosyltransferases for Le y synthesis, and presently, we found higher expression of Le y in the vessel wall with atherosclerotic plaque than without plaque ( Figure 6C and 6D) . The observation implies the positive correlation of Le y and atherosclerosis progression. Although CD31 staining showed the intact endothelial lining in the vessel wall without plaque, the signal of Le y was weak and sparse in that area, indicating the lower expression of Le y in normal endothelium and an inflammatory environment results in Le y upregulation. In another in vivo investigation, increased Le y expression has been found on vascular endothelium from patients with rheumatoid arthritis where Le y was cytokine inducible. 20 These results certainly identify the significance of Le y in vascular inflammation. It is more interesting to notice that the result of tissue Western blot showed several increasing bands in vessels after ligation ( Figure 6A) , indicating that there are some specific molecules carrying Le y that are induced in the injured vasculature and probably involve in leukocyte adhesion. Further studies are needed to identify these molecules.
By comparing the efficacy of rTMD1 proteins expressed by Pichia and mammalian expression systems, there were no significant differences in their functions between both of the proteins. Our previous studies 10 have illustrated that the efficiency of Pichia-rTMD1 in the inhibition of lipopolysaccharideinduced inflammation is comparable with that of m-rTMD1 by several in vitro assays. These findings suggest that although the glycosylation of these 2 rTMD1 proteins are very different, their functions are similar, meaning that the glycosylation would not affect the Le y -binding ability of TMD1.
We verified the treatment of rTMD1 by directly detecting the presence of administered rTMD1 on the inflamed vessels of carotid ligation and atherosclerosis models. The signals of rTMD1 were partially detected at the endothelial layer. Because the denudation occurred in aortic arches, we observed that the intensity of rTMD1 staining was weak in atherosclerotic samples. However, rTMD1-positive staining pattern was similar to CD31 and Le y , indicating that rTMD1 was supposed to deposit on inflamed endothelium by binding Le y . Notably, the half-life of rTMD1 in circulation reported by our group is 3 to 4 hours, and the injected rTMD1 exists in circulation last for 12 hours. 10 In ligated arteries, rTMD1 was still detectable in samples harvested at 16 hours after injection, suggesting that the binding of administered rTMD1 to inflamed endothelium may prevent the rapid rTMD1 clearance in circulation; and further, the duration of the efficacy of injected rTMD1 might be extended.
Various in vivo inflammatory models of the anti-inflammatory ability of rTMD1 have been well exhibited. 7-10 Here, we initially administrated rTMD1 into apolipoprotein E-deficient to verify whether the protein would control atherosclerosis progression. The results showed that atherosclerotic plaque formation and macrophage accumulation were significantly reduced by rTMD1 treatment. TM is known to be the membrane protein representing as a protector on vascular endothelium. When endothelial cells are damaged, TM expression level is reduced. Loss of TM on endothelium is also found in atherosclerotic coronary arteries, 35 which dampens the anticoagulation and anti-inflammation mediated by TM/thrombin complex. Further thrombosis and inflammation occur in the atherosclerotic region. In addition, soluble TM can be detected in plasma of the patients with coronary heart disease, and some clinical data showed that the levels of soluble plasma TM may be inversely associated with coronary heart disease. 36, 37 According to our studies, it suggests that rTMD1 has the potential effect on suppressing atherosclerosis.
In summary, the present works provide evidences that Le y is an inflammation-induced carbohydrate on endothelial cells and mediates leukocyte adhesion. However, rTMD1 functions as an inhibitor in Le y /leukocyte binding; therefore, leukocyte recruitment is consequently suppressed in vitro and in vivo. This study yields an important mechanism underlying the therapeutic function of rTMD1 in vascular diseases.
